Quick answer: Retatrutide documentation does not arrive as one bundle, and it should not be judged as one. Files arrive at four points — before quotation, before you confirm the order, before release or shipment, and after receipt — and at each point they support a different decision. What you can reasonably hold at each point also depends on whether you are buying vials that already exist or vials that have not been made yet. This guide sets out both paths, explains what each line of a typical vial COA can and cannot tell you, and lists what a document pack does not establish.
This article is for B2B buyers of research-use Retatrutide (LY3437943) lyophilized vials. If you are still preparing the enquiry, start with the Retatrutide RFQ checklist. This page picks up where that one stops: files have started arriving and you have to decide whether they are enough for the next step.
1. Four decision points, two kinds of order
| Stage | In-stock vials | Made-to-order vials | The decision it supports |
|---|---|---|---|
| Before quotation | Example documents; which tests are run and on what (bulk peptide or finished vials); which batches are in stock | Example documents; target specification; planned test scope | Is this supplier worth a quotation round? |
| Before order confirmation or deposit | Documents for the batch proposed for your order; acceptance and re-test arrangements | A written list of which documents will be delivered after production, when, and how release and payment milestones relate to them | Can I commit money on these terms? |
| Before release or shipment | Final batch documents and their link to the goods being shipped | Documents for the batch actually produced, with the agreed test results | Do the goods about to ship match what was agreed? |
| After receipt | Check the goods against the documents; run your own test as agreed | Do I accept this delivery, and do I reorder? | |
Two mistakes are common. The first is treating an example COA as evidence about your goods: it shows how a supplier documents a batch, and nothing about the batch you will receive. The second is asking for finished-batch results before paying for an order that has not been produced. Final test results for finished vials cannot exist before those vials are produced and tested. Existing raw-material reports may be available, but they do not replace finished-batch documentation. What can be fixed at that point is the list of deliverables and what happens if they are not delivered.
2. What the lines on a vial COA can and cannot tell you
The table below describes the fields that typically appear on a lyophilized-vial COA, including ours. It is a field guide, not a specific batch record.
| Field | What it tells you | What it does not tell you |
|---|---|---|
| Batch number | The identifier the supplier uses for this material. Ask what it refers to: the bulk peptide batch, the fill run, or both | A date is not a unique identifier. Linking vials to a production run needs a unique production record or a documented link between numbers, not a filling date alone |
| Test date, filling date, issue date | The dates the supplier records for each step | They are statements on a document. A recent issue date does not mean a recent test; ask which sample each result was measured on, and when |
| Identity by mass spectrometry | That the measured mass is consistent with Retatrutide (CAS 2381089-83-2). The report should state the observed value and the theoretical value it was compared against, on the same basis | Sequence confirmation: a matching intact mass does not confirm the full sequence. Nor freedom from related impurities. Assessing those needs a suitable separation method and its data, and even a good method is limited by what it can resolve and detect |
| Purity by RP-HPLC (area %) | The main peak's share of detected peak area under that method | How much peptide is in the vial. Purity is a ratio, not a quantity — see purity versus content |
| Fill amount or label claim, “method: filling record” | What the production record states. Ask whether that is a target quantity, a calculated quantity or an in-process measurement | A measured peptide content of the finished vial. That takes a quantitative analysis of finished vials |
On many vial COAs, including ours at present, identity and purity are measured on the bulk peptide used for production and the fill amount is taken from the filling record. Our COA says so in its footer. We would rather state it than let a buyer assume the finished vial was assayed.
When two purity figures for the same product differ, the method may be part of the explanation: column, gradient, wavelength and sample load all affect area-percent results. But a difference in method is a possible explanation, not a finding. Interpreting two figures needs the method, the identity of the sample behind each figure, and the test record. How a laboratory report is tied to delivered goods is covered in what a batch-matched third-party COA proves.
3. Before you commit money: what each file is for
- Batch documents (in-stock) or a deliverables list (made-to-order). Have the batch identifier, or the agreed deliverables, written on the quotation or proforma invoice so the commercial document and the quality documents point at each other. If missing: you are paying against an example, not against your goods.
- Chromatogram, peak table and mass spectrum behind the COA figures. A COA may be a summary with the underlying data held separately; that is normal. What matters is that the data exists and can be supplied for the batch in question. If it cannot be supplied: the figure cannot be reviewed, only believed.
- A written basis for “mg per vial”: production record, in-house assay, or third-party assay on finished vials, and whether the figure means net peptide or total powder. If missing: a later content result has nothing agreed to be compared against.
- A third-party report, where one exists. Check which product, vial size and sample it was issued for. A report on one vial size does not establish the content of another, even from the same bulk peptide. Verify it with the issuing laboratory.
- Acceptance terms: which laboratory, which measurement, how many vials, what tolerance, and what happens outside it. If left open: after payment it is a dispute rather than a term.
- An SDS, for your receiving site and carrier.
4. Before shipment and at receipt: do the identifiers connect?
The identifiers on the vial label, the COA, the shipping record and any third-party report should be the same, or be connected by a clear record you can check. Suppliers do re-code batches, and a laboratory may use its own sample name. Different identifiers may be acceptable when traceable records establish that they refer to the same material or production batch; a mapping table alone does not establish that link. Where a document has been corrected, the reason, date and version should be recorded, and a third-party report is never altered after issue. An unexplained difference is a problem, because you cannot tell re-coding from substitution from the outside, and neither can your own customer. Resolve it before the goods go into stock.
If you asked for each SKU from a single fill run, confirm it here as well.
5. Your own test is part of the pack
Several buyers this quarter told us the same thing in different words: an internal document is not enough, and they will send vials from the delivery to a laboratory of their choosing. We think that is the right instinct. Testing vials you selected from the delivery reduces reliance on supplier-selected samples. Its evidential value still depends on documented sampling, sample identification, handling and the laboratory's methods, so record which batch the sampled vials came from and how they were taken.
To make the test useful, agree beforehand which laboratory and which measurement — purity by HPLC, identity by MS and a quantitative content method are three separate requests — and keep the vials sealed and stored as instructed until they are sent. The longer walkthrough is on our supplier verification page.
6. What this document pack does not establish
- Pharmaceutical GMP status. WUMO does not hold a pharmaceutical GMP certificate for these research-use vials, and we do not present any other certificate as one. For any certificate you are shown, by anyone, check three things: the legal entity named, the site, and the scope.
- Long-term stability. We do not currently have long-term real-time stability data for Retatrutide in our vial presentation. Our storage guidance follows general practice for lyophilized peptides; it is not a product-specific stability study.
- Anything about human use. These are research-use materials. We do not provide dosing or clinical-use guidance, and nothing in the pack should be read as such.
- Results outside the documented test scope. Do not assume a test was performed unless the documentation identifies it and its result. Endotoxin, sterility, residual solvents, counter-ion and water content are separate analyses; confirm the testing your intended research use and agreed specification require before ordering, since additional analyses may affect price and lead time.
7. What WUMO provides
- Public files on the Retatrutide product page are for initial evaluation.
- Order-related documents — which files, for which batch, at which point — are agreed before order confirmation, following the stages above.
- Your own testing of vials from your delivery, at a laboratory you choose, is welcomed.
- Single fill run per SKU: tell us at enquiry stage and we confirm before quoting whether the quantity can be supplied that way.
Frequently Asked Questions
What documents should I review before paying for Retatrutide vials?
For in-stock vials: the documents for the batch proposed for your order, the data behind the COA figures, the written basis of the mg-per-vial figure, any third-party report for that product and vial size, and agreed acceptance terms. For made-to-order vials: a written list of the documents to be delivered after production, and how release and payment relate to them.
Is an example COA enough to place an order?
Not by itself. It shows how a supplier documents a batch. For made-to-order supply, an example COA can support initial review when accompanied by agreed specifications, testing deliverables and release conditions; it does not establish the quality of the future batch.
Can I get a batch COA before a made-to-order batch is produced?
Final results for finished vials cannot be available before those vials are produced and tested. Reports on the raw material to be used may already exist, but they do not replace finished-batch documentation. Agree the deliverables, the test scope and the release conditions, and review the actual batch documents before shipment.
Does the purity on a Retatrutide COA tell me how much peptide is in the vial?
No. HPLC purity is the main peak's share of detected peak area. The amount of peptide per vial is a separate measurement, and on many vial COAs the fill amount comes from the filling record rather than from an assay of the finished vial.
Why can two purity figures for the same peptide differ?
Method conditions affect area-percent results, so method is one possible reason. To interpret a difference you also need to know which sample each figure was measured on, and when.
Do the batch numbers on the label, COA and third-party report have to be identical?
They should be the same, or connected by traceable records that establish they refer to the same material or production batch. A mapping on its own does not establish that link. An unexplained difference should be resolved before you accept the goods.
Send us your document list
Tell us the vial size, quantity, whether you need in-stock or made-to-order supply, the documents your internal review requires, and the laboratory you plan to use. We will tell you which files exist for a current batch, which can be arranged per project, and which we cannot provide. Send your Retatrutide documentation requirements.
For laboratory research use only. Not for human or veterinary use.